Gland Pharma Limited

rs 25

November 03, 2025 BSE Limited Corporate Relationship Department Phiroze Jeejeebhoy Towers 25th floor, Dalal Street Mumbai - 400 001 Scrip Code: 543245 Dear Sir/Madam, National Stock Exch

63%

me Total Income Gross Profit(1) 842 596 15,710 14,654 9,331 8,304 Gross Profit margin (%) 63% 59% 6% 41% 7% 12% 15,056 575 15,631 9,845 65% -1% 46% 1% -5% 29,925 28,075 1,417

59%

otal Income Gross Profit(1) 842 596 15,710 14,654 9,331 8,304 Gross Profit margin (%) 63% 59% 6% 41% 7% 12% 15,056 575 15,631 9,845 65% -1% 46% 1% -5% 29,925 28,075 1,417 31,3

6%

Income Gross Profit(1) 842 596 15,710 14,654 9,331 8,304 Gross Profit margin (%) 63% 59% 6% 41% 7% 12% 15,056 575 15,631 9,845 65% -1% 46% 1% -5% 29,925 28,075 1,417 31,342

41%

me Gross Profit(1) 842 596 15,710 14,654 9,331 8,304 Gross Profit margin (%) 63% 59% 6% 41% 7% 12% 15,056 575 15,631 9,845 65% -1% 46% 1% -5% 29,925 28,075 1,417 31,342 19,17

7%

oss Profit(1) 842 596 15,710 14,654 9,331 8,304 Gross Profit margin (%) 63% 59% 6% 41% 7% 12% 15,056 575 15,631 9,845 65% -1% 46% 1% -5% 29,925 28,075 1,417 31,342 19,175 1

12%

Profit(1) 842 596 15,710 14,654 9,331 8,304 Gross Profit margin (%) 63% 59% 6% 41% 7% 12% 15,056 575 15,631 9,845 65% -1% 46% 1% -5% 29,925 28,075 1,417 31,342 19,175 1,111

65%

54 9,331 8,304 Gross Profit margin (%) 63% 59% 6% 41% 7% 12% 15,056 575 15,631 9,845 65% -1% 46% 1% -5% 29,925 28,075 1,417 31,342 19,175 1,111 29,186 16,678 64% 59% 7% 28%

1%

331 8,304 Gross Profit margin (%) 63% 59% 6% 41% 7% 12% 15,056 575 15,631 9,845 65% -1% 46% 1% -5% 29,925 28,075 1,417 31,342 19,175 1,111 29,186 16,678 64% 59% 7% 28% 7%

46%

8,304 Gross Profit margin (%) 63% 59% 6% 41% 7% 12% 15,056 575 15,631 9,845 65% -1% 46% 1% -5% 29,925 28,075 1,417 31,342 19,175 1,111 29,186 16,678 64% 59% 7% 28% 7% 15%

5%

oss Profit margin (%) 63% 59% 6% 41% 7% 12% 15,056 575 15,631 9,845 65% -1% 46% 1% -5% 29,925 28,075 1,417 31,342 19,175 1,111 29,186 16,678 64% 59% 7% 28% 7% 15% EBITDA(2

64%

5,631 9,845 65% -1% 46% 1% -5% 29,925 28,075 1,417 31,342 19,175 1,111 29,186 16,678 64% 59% 7% 28% 7% 15% EBITDA(2) EBITDA margin(%)(3) Adj.EBITDA(4) 3,139 2,961 6% 3,678 -15

Base business

1

Investor Relations

1

Base business

• QoQ saw improved sales of some of the key products. • For H1FY26, our own product sales grew by 19%; while the tech-transfer & CMO product revenue went down by 53%. 17 GLAND PHARMA Thank You

Investor Relations

Sampath Kumar Pallerlamudi Company Secretary & Compliance Officer Shriniwas P. Dange Investor Relations investors@glandpharma.com Corporate Office Gland Pharma Limited Plot No. 11 & 84, TSIIC Phase: IV Pashamylaram (V), Patancheru (M), Sangareddy District Hyderabad 502307, Telangana, India 543245 GLAND GLAND:IN 18